scholarly journals Recent Updates in Experimental Research and Clinical Evaluation on Drugs for COVID-19 Treatment

2021 ◽  
Vol 12 ◽  
Author(s):  
Houwen Zou ◽  
Yuqi Yang ◽  
Huiqiang Dai ◽  
Yunchuang Xiong ◽  
Jing-Quan Wang ◽  
...  
Keyword(s):  
Public Health ◽  
Clinical Trial ◽  
Experimental Research ◽  
Clinical Evaluation ◽  
Clinical Studies ◽  
Virus Disease ◽  
Clinical Trial Data ◽  
Trial Data ◽  
Global Public Health ◽  
The World

Since the outbreak of corona virus disease 2019 (COVID-19) in Wuhan (China) in December 2019, the epidemic has rapidly spread to many countries around the world, posing a huge threat to global public health. In response to the pandemic, a number of clinical studies have been initiated to evaluate the effect of various treatments against COVID-19, combining medical strategies and clinical trial data from around the globe. Herein, we summarize the clinical evaluation about the drugs mentioned in this review for COVID-19 treatment. This review discusses the recent data regarding the efficacy of various treatments in COVID-19 patients, to control and prevent the outbreak.

scholarly journals The Development of Tumor Neoantigen Vaccine Immunotherapy

2019 ◽  
Vol 78 ◽  
pp. 01005
Author(s):  
Wanqiu Wang
Keyword(s):  
Clinical Trial ◽  
Tumor Immunology ◽  
Somatic Mutations ◽  
Clinical Trial Data ◽  
Trial Data ◽  
Normal Cells ◽  
The Core ◽  
The World ◽  
Recent Clinical Trial ◽  
Future Direction

Activating the immune system to fight against cancers has long been a goal in immunology and oncology studies. Recent clinical-trial data proved that boosting the activity of endogenous T cells to destroy cancer cells has great potential in controlling the progression of a variety of human malignancies. In essence, neoantigen is at the core of tumor immunology. Autologous T lymphocytes could distinguish tumor cells from normal cells by recognizing neoantigens, which are tumor specific. Neoantigens are derived from genome somatic mutations of tumors, and there are different approaches to predict and identify them with increasing accuracy. Neoantigens are tumor specific, which are ideal and attractive targets for tumor immunotherapies; many neoantigen-based clinical trials are being carried out around the world. In this review, we will discuss the recent advances of tumor neoantigen vaccine immunotherapy, and present the potential obstacle and future direction of this approach.

scholarly journals Transparency in clinical trials

2021 ◽  
Author(s):  
ChS Pavlov ◽  
DL Varganova ◽  
AA Svistunov ◽  
C Gluud
Keyword(s):  
Clinical Trial ◽  
Clinical Trials ◽  
Technology Development ◽  
Personal Data ◽  
Clinical Trial Data ◽  
Trial Data ◽  
Positive Effects ◽  
The World ◽  
Information Technology Development ◽  
Meta Analyses

In the age of information technology development, healthcare professionals around the world have the opportunity to simultaneously access advanced scientific developments, modern achievements, and the results of new clinical trials. The clinical guidelines of the international medical communities are based on the results of meta-analyses of clinical trial data. As new medical challenges emerge, clinical trial data are reviewed and re-analyzed. Unfortunately, to date, the results of not all studies are made public, or are presented selectively, indicating the positive effects of a particular technology (intervention), which makes it difficult to critically evaluate the results of work and makes the task of assessing the true effectiveness of the intervention more difficult. The problem of transparency of research data with the preservation of personal data of participants remains relevant for decades. This article is focused on possible ways of solving this problem and the analysis of the current situation in the world.

scholarly journals Lack of clinical trial data transparency and current solutions

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Tabassom Baghai
Keyword(s):  
Clinical Trial ◽  
Clinical Research ◽  
World Health Organization ◽  
Clinical Trial Data ◽  
Trial Data ◽  
World Health ◽  
The World ◽  
Data Transparency ◽  
Health Organization ◽  
The U.S

An ongoing challenge in clinical research is the inaccessibility of clinical trial data, which prevents physicians from making an informed decision with regards to patient care. The U.S. Food and Drug Administration (FDA) as well as the World Health Organization (WHO) recently called for all trial data to be registered and made publically available. However, this issue is still ongoing and there are several measures currently being enforced to rectify these concerns. Potential solutions, such as regulations, campaigns, and possible conse- quences, for increasing transparency in clinical trial data will be discussed. RÉSUMÉ L’inaccessibilité des données provenant d’essais cliniques constitue un défi constant en recherche clinique, puisqu’elle empêche les médecins de prendre des décisions éclairées quant aux soins de leurs patients. Récemment, le Secrétariat américain aux produits alimentaires et pharmaceutiques (FDA) ainsi que l’Organisation mondiale de la Santé (OMS) ont demandé que toutes les données d’essais cliniques soient enregistrées et mises à la disposition du public. Toutefois, ce problème persiste et plusieurs mesures ont été mises en place pour répondre à ces préoccupations. Des solutions possibles dont des réglementations, des campagnes et des sanctions possibles pour améliorer la transparence en ce qui concerne les données d’essais cliniques seront discutées. 

scholarly journals Therapeutic Application of Chloroquine and Hydroxychloroquine in Clinical Trials for COVID-19: A systematic review

2020 ◽  
Author(s):  
Divya RSJB Rana ◽  
Santosh Dulal
Keyword(s):  
Public Health ◽  
Systematic Review ◽  
Clinical Trial ◽  
Clinical Trials ◽  
Virus Disease ◽  
Global Public Health ◽  
Therapeutic Application ◽  
Clinical Trial Registries ◽  
Corona Virus

AbstractThe corona virus disease -2019 (COVID-19) pandemic has caused a massive global public health havoc. Recent published clinical trials show conflicting data for use of chloroquine/hydroxychloroquine for COVID-19. This study meticulously evaluated the various dosages of chloroquine and hydroxychloroquine utilized in clinical trials registered in Chinese and US clinical trial registries for the treatment of pneumonia caused by SARS-CoV-2. Moreover, the results of published clinical trials and in vitro studies using chloroquine and hydroxychloroquine relevant to the disease are discussed.

scholarly journals COVID-19 Vaccine Race: An Overview and Update

2021 ◽  
Vol 11 (2) ◽  
pp. 171-177
Author(s):  
Md. Rayhan Chowdhury ◽  
Shirmin Islam ◽  
Mohammad Nurul Matin
Keyword(s):  
Clinical Trial ◽  
Vaccine Development ◽  
Vaccine Candidate ◽  
Clinical Trial Data ◽  
Trial Data ◽  
Phase Iii ◽  
Health Crisis ◽  
Phase Iii Clinical Trials ◽  
Successful Vaccine ◽  
The World

A sudden health crisis has shut down the entire world for almost a year due to a new virus called Covid-19 and thus the WHO has declared the COVID-19 as a pandemic disease. As vaccines stimulate the immune system to fight against future infections, thereby conferring immunity, so far, vaccine development in a race throughout the world. Therefore, disseminating the overview of the vaccine development at present with their critical situation for COVID-19 is the aim of this review. The world is looking eagerly for a potential vaccine candidate that can save every life. Here, we reported the overview of the possible types of vaccines against Covid-19 as well as a glimpse of vaccine race with different phases of clinical trial data, comparison of the rate of success of phase-III clinical trials and their safety, and drawbacks with the present status. We have studied literature from clinical trial data of respective vaccine candidates published in the journals and collected data from databases dedicated to corona vaccine and the vaccine company's website to enrich our review and aiming to focus on clinical trial data stages, how consequences it faces, and how to position it belongs towards a successful vaccine candidate. Keywords: COVID-19, SARS-CoV-2, COVID-19 vaccine, Clinical trial.

scholarly journals Clinical Trial Data Management in Environmental Health Tailored for an African Setting

2020 ◽  
Vol 17 (2) ◽  
pp. 402
Author(s):  
Patricia Nicole Albers ◽  
Caradee Yael Wright
Keyword(s):  
Public Health ◽  
Clinical Trial ◽  
Data Management ◽  
Environmental Health ◽  
Meteorological Data ◽  
Clinical Trial Data ◽  
Patient Data ◽  
Trial Data ◽  
Management Tool

Clinical trial data management tools are widely available—some free to access and others relatively expensive, particularly for low- and middle-income countries. Such tools also do not always permit adaptation for local conditions nor include options to capture environmental and meteorological data. In the context of climate change and pressing environmental health threats, more studies that aim to assess the impacts of environmental change on public health are being carried out. Here, using freely available software, we tailor-made a clinical trial data management tool that managed all aspects of an intervention-based clinical trial to assess the impact of personal solar ultraviolet radiation exposure on vaccine effectiveness. Data captured and associated procedures included patient data, scheduling, reporting, analysis and data management. Moreover, patient enrolment, recruitment, follow-up and decision-making in response to patient data were managed. Given the multidisciplinary study approach, the tool also managed all environmental and meteorological data for the rural African study site. Application of the tool ensured efficient communication between rural sites, a relatively high overall participant response rate (87%) and minimal loss to follow-up. This study suggests that it is possible to tailor-make a clinical trial data management tool for environmental and public health studies.

Sign in / Sign up

Export Citation Format

Share Document